TherapeuticsMD (TXMD) Rating Increased to Buy at Zacks Investment Research
TherapeuticsMD (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The firm presently has a $6.25 price target on the stock. Zacks Investment Research‘s target price suggests a potential upside of 12.41% from the company’s previous close.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Several other research analysts have also weighed in on TXMD. Cantor Fitzgerald set a $27.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research report on Sunday, October 14th. BidaskClub lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Tuesday, July 3rd. Oppenheimer set a $12.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research report on Monday, July 30th. ValuEngine lowered TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Saturday, July 28th. Finally, JPMorgan Chase & Co. set a $11.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, August 15th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. TherapeuticsMD currently has an average rating of “Buy” and a consensus target price of $13.88.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, July 30th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The business had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $4.23 million. During the same period in the prior year, the company earned ($0.10) EPS. The company’s revenue for the quarter was down 11.6% compared to the same quarter last year. Analysts expect that TherapeuticsMD will post -0.63 earnings per share for the current fiscal year.
In related news, Director Brian Bernick sold 91,400 shares of the stock in a transaction on Friday, October 5th. The stock was sold at an average price of $5.93, for a total value of $542,002.00. Following the completion of the sale, the director now directly owns 242,000 shares in the company, valued at approximately $1,435,060. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert G. Finizio sold 92,000 shares of the stock in a transaction on Thursday, October 11th. The shares were sold at an average price of $5.65, for a total value of $519,800.00. Following the completion of the sale, the chief executive officer now owns 18,485,559 shares of the company’s stock, valued at $104,443,408.35. The disclosure for this sale can be found here. Insiders sold a total of 1,542,000 shares of company stock worth $9,621,174 over the last ninety days. Corporate insiders own 22.85% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fox Run Management L.L.C. acquired a new stake in TherapeuticsMD in the 2nd quarter valued at $121,000. Xact Kapitalforvaltning AB increased its holdings in TherapeuticsMD by 96.3% in the 1st quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after purchasing an additional 15,600 shares in the last quarter. Affiance Financial LLC acquired a new stake in TherapeuticsMD in the 2nd quarter valued at $156,000. Barclays PLC increased its holdings in TherapeuticsMD by 33,787.3% in the 1st quarter. Barclays PLC now owns 37,276 shares of the company’s stock valued at $182,000 after purchasing an additional 37,166 shares in the last quarter. Finally, Twin Focus Capital Partners LLC acquired a new stake in TherapeuticsMD in the 2nd quarter valued at $187,000. Hedge funds and other institutional investors own 66.14% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Read More: Short Selling Stocks and Day Traders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.